Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference

Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City.

Rhea-AI Summary

Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will engage in one-on-one meetings to showcase their value proposition and introduce their upcoming Co-Dx PCR testing platform.

The company notes that their PCR platform, which includes the PCR Home™, PCR Pro™, mobile app, and associated tests, is currently pending regulatory review by the FDA and other bodies and is not yet commercially available.

Argus Session date unavailable

-4.91% session move Open Argus

Details

News Market Reaction – CODX

The recorded move for CODX in the trading session of this news was -4.91%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.

The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company’s value proposition and to the upcoming Co-Dx PCR* testing platform.

More information about the conference can be found here.

*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.

Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader’s convenience and do not constitute an endorsement by the Company.

Company Contact:

Andrew Benson

Head of Investor Relations

+1.801.438.1036

investors@codiagnostics.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Co-Diagnostics (CODX) participating in the D. Boral Conference?

Co-Diagnostics is participating to meet with institutional investors and present their value proposition and upcoming Co-Dx PCR testing platform through one-on-one meetings.

When and where is the D. Boral Capital Inaugural Global Conference featuring CODX taking place?

The conference is taking place on May 14, 2025, in New York City.

What products will Co-Diagnostics (CODX) showcase at the D. Boral conference?

The company will showcase their upcoming Co-Dx PCR platform, including PCR Home™, PCR Pro™, mobile app, and associated tests, which are currently pending FDA review.

Is the Co-Dx PCR testing platform currently available for purchase?

No, the Co-Dx PCR platform is not yet available for sale as it is still subject to review by the FDA and other regulatory bodies.